- Report
- June 2024
- 200 Pages
Global
From €7348EUR$7,950USD£6,125GBP
- Report
- June 2024
- 200 Pages
Global
From €7348EUR$7,950USD£6,125GBP
- Drug Pipelines
- March 2024
- 210 Pages
Global
From €7348EUR$7,950USD£6,125GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4575EUR$4,950USD£3,814GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €2542EUR$2,750USD£2,119GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €2542EUR$2,750USD£2,119GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €2542EUR$2,750USD£2,119GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €2542EUR$2,750USD£2,119GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €2542EUR$2,750USD£2,119GBP
- Report
- November 2023
- 630 Pages
Global
From €8781EUR$9,500USD£7,320GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €3004EUR$3,250USD£2,504GBP
- Drug Pipelines
- November 2023
- 30 Pages
Global
From €2542EUR$2,750USD£2,119GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2542EUR$2,750USD£2,119GBP
- Report
- January 2022
- 60 Pages
Global
From €3651EUR$3,950USD£3,043GBP
- Report
- February 2021
- 50 Pages
Global
From €3004EUR$3,250USD£2,504GBP
- Report
- November 2025
- 200 Pages
Global
From €7348EUR$7,950USD£6,125GBP
- Report
- November 2025
- 200 Pages
Global
From €7348EUR$7,950USD£6,125GBP
- Report
- November 2025
- 200 Pages
Global
From €7348EUR$7,950USD£6,125GBP
- Report
- June 2024
- 200 Pages
Global
From €7348EUR$7,950USD£6,125GBP
- Report
- June 2024
- 200 Pages
Global
From €7348EUR$7,950USD£6,125GBP

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies.
The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments.
Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more